Literature DB >> 10524521

The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases.

M Beylot-Barry1, B Vergier, B Masquelier, M Bagot, P Joly, P Souteyrand, L Vaillant, M F Avril, N Franck, S Fraitag, M Delaunay, L Laroche, E Estève, P Courville, P Dechelotte, C Beylot, A De Mascarel, J Wechsler, J P Merlio.   

Abstract

We studied 21 HIV-associated lymphomas with cutaneous presentation to determine whether they showed features of primary cutaneous lymphoma arising fortuitously or whether they represented the cutaneous involvement of AIDS systemic lymphoma. Besides rare mycosis fungoides (n = 3), which shared typical clinicopathologic lesions, nonepidermotropic large-cell lymphomas (n = 18) were predominant. They frequently presented as a solitary nodule or tumor. Seven of the eight large T-cell lymphomas had a CD30-positive (CD30+) phenotype but did not express ALK protein. Overexpression of p53 protein was observed in six cases. Although EBV-EBER transcripts were detected in two of them, LMP1 protein was absent. Except for their original prevalence, the features of these T-cell CD30+ cutaneous lymphomas were the same as in immunocompetent patients. The 10 B-cell cutaneous lymphoma were immunoblastic or centroblastic lymphomas, with a differential expression of BCL-6 and Syndecan. Four of them expressed CD30, EBER-EBV transcripts, and LMP1 and p53 proteins. This B-cell CD30+ EBV+ phenotype contrasts with cutaneous lymphoma in immunocompetent patients. Human herpesvirus 8 was not involved in lymphomagenesis since its sequences were detected in a single patient with Kaposi's sarcoma and Castleman's disease. These lymphomas occurred in severely immunocompromised patients with a low CD4 count. Death was due to immunodepression rather than to lymphoma spread, suggesting avoiding aggressive immunosuppressive treatment in such patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524521     DOI: 10.1097/00000478-199910000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 2.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

3.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.

Authors:  Antonino Carbone; Annunziata Gloghini; Emanuela Vaccher; Michaela Cerri; Gianluca Gaidano; Riccardo Dalla-Favera; Umberto Tirelli
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

Review 4.  Infectious agents in cutaneous T-cell lymphoma.

Authors:  Ezra D Mirvish; Rebecca G Pomerantz; Larisa J Geskin
Journal:  J Am Acad Dermatol       Date:  2010-08-07       Impact factor: 11.527

5.  Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.

Authors:  Joséphine Franceschi; Marine Ehret; Laetitia Visseaux; Anne Durlach; Coralie Barbe; Éric Durot; Florent Grange
Journal:  Acta Derm Venereol       Date:  2022-03-22       Impact factor: 3.875

6.  Review of HIV-Related Cytopathology.

Authors:  Tee U Lang; Walid E Khalbuss; Sara E Monaco; Pam Michelow; Liron Pantanowitz
Journal:  Patholog Res Int       Date:  2011-04-07

7.  A Case of an Unusually Aggressive Cutaneous Anaplastic Large T-Cell Lymphoma in an HIV Patient Treated with CHOP.

Authors:  Jorge Hurtado-Cordovi; Louay Hanna; Vladimir Gotlieb; Alan S Multz; Anastasia Pigal
Journal:  Case Rep Oncol Med       Date:  2011-12-08

8.  Two Different Extranodal Lymphomas in an HIV+ Patient: A Case Report and Review of the Literature.

Authors:  Clara Bertuzzi; Elena Sabattini; Francesco Bacci; Claudio Agostinelli; Gian Gaetano Ferri
Journal:  Case Rep Hematol       Date:  2019-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.